
Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B
CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Oxford-based-Alethio-Therapeutics-unveiled-a-90M-Series-A-today-to-advance-its-therapies-for-myeloproliferative-neoplasms--and-also-announced-for-the-first-time-that-ATX-011s-target-will-be-G6B-e3rpr7h
Published
November 5, 2026
Duration
15 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#oxfordbasedalethio #therapies #myeloproliferativeneoplasms #lifesciences
